header

Obesity-news.com
THE LATEST IN OBESITY RESEARCH AND WEIGHTLOSS DRUG DEVELOPMENT

    Join our list More information

    

Saturday, January 28, 2012

February 22, 2011. Transcripts of company press conferences following Contrave's committee approval and FDA rejection are now on-line. We are also working on an analysis that will be published in a few days:

  Transcript of the December 8 press conference. (subscribers)
  Transcript of February 1 press conference. (subscribers)

If you are a current subscriber, you may access the files above using your user name and password. Non-subscribers may gain access by subscribing on-line. Over the next few days we will also make these transcripts available, along with the analysis at a cost of $49. This is for the Contrave package only, and it does not allow access to the rest of our database. Each new package will be available for 30 days only following publication.

We are in the process of adding new updates to our investigational drug, and pharmaceutical company databases. The next investigational drug analysis package to be offered will cover lorcaserin (Lorqess). It should be available in March.

header

Obesity-news is a publication of Hirsch Communications. An on-line subscription is $104.00 per month, payable in advance by American Express, VISA or Mastercard. Subscribing is simple using our secure on-line subscription form. A yearly subscription is also available for $999 per year through EBSCO or Swets Blackwell subscription services. Please contact them for more information. Obesity-news also accepts fax orders at 703/960-7462. Copyright 1997-2011, all rights reserved.

IMPORTANT: All information in this publication is believed to be accurate and true. Publisher is not liable for omissions or inaccuracies. Information in this newsletter is for educational purposes only and should not be construed as medical advice, or be used in lieu of consultation with a health care provider.